trending Market Intelligence /marketintelligence/en/news-insights/trending/l_yQGASw7H0qK-eZEnAepg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Galmed Pharmaceuticals chairman resigns; CEO named as replacement

Blog

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Video

Climate Credit Analytics: Linking climate scenarios to financial impacts

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge


Galmed Pharmaceuticals chairman resigns; CEO named as replacement

Galmed Pharmaceuticals Ltd. said Chairman Chaim Hurwitz resigned on Dec. 25 to pursue other opportunities, effective immediately.

The Tel Aviv, Israel-based company said CEO and board member Allen Baharaff will replace Hurwitz, subject to shareholder approval.

Hurwitz joined the board in 2011 and has been a member of the audit, nominating and tech committees.

Baharaff, who co-founded the company in 2000, was named CEO in 2012 and president in 2015.

Galmed also appointed board member David Sidransky as chair of the nominating committee and lead independent director, a newly created role that serves as a liaison between the chairman and the independent directors.

Galmed develops therapeutics to treat liver diseases.